Vanda Pharmaceuticals Inc announced that a HETLIOZ patent, number 10,071,977 (‘977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The ‘977 patent was issued by the United States Patent and Trademark Office on September 11, 2018 and expires in February 2035. Prior to this newly listed ‘977 patent, the HETLIOZ Orange Book listed patent with the latest expiry date was set to expire in May 2034.
Related Posts
Upcoming Events
04Apr
Sleep Education Consortium Conference 2024
DoubleTree by Hilton Hotel Houston - Greenway Plaza
04Apr
46th Annual Southern Sleep Society Meeting
Hotel Avalon, Autograph Collection
05Apr
IAOS Blueprint April 2024
Austin
05Apr
ScanEdge: Digital Profitability Symposium
Glidewell Clinical Education Center
05Apr
Melbourne Florida Sleep Convergence 2024
DoubleTree Suites by Hilton Melbourne Beach Oceanfront
No event found!